NYSE Flags VolitionRx Over Stockholders' Equity Shortfall, Orders Compliance Plan

NYSE Flags VolitionRx Over Stockholders’ Equity Shortfall

VolitionRx Ltd., a multi‑national epigenetics company, says it received a notice from NYSE American on Feb. 6 advising the company is not in compliance with the exchange’s continued listing standards under Section 1003(a)(i), (ii) and (iii) of the Company Guide. The notice cites minimum stockholders’ equity thresholds tied to recurring losses — $2.0 million, $4.0 million or $6.0 million depending on the number of recent loss years — and states VolitionRx is not eligible for listed exemptions, including the market‑capitalization exemption for companies above $50 million.

The exchange requires VolitionRx to submit a plan by March 8, 2026 that describes actions taken or planned to regain compliance by Aug. 6, 2027. If NYSE American accepts the plan, the company will be subject to periodic reviews and quarterly monitoring to evaluate progress. Failure to submit an acceptable plan, lack of sufficient progress or failure to achieve compliance by the deadline could prompt delisting proceedings under the exchange’s rules, though the company may appeal any staff delisting determination under Section 1010 and Part 12.

The notice does not immediately affect the listing of VolitionRx common stock, which continues to trade on NYSE American under the symbol VNRX with a “.BC” designation indicating below‑compliance status, the company says. VolitionRx stresses the exchange communication does not alter day‑to‑day operations, ongoing research programs in epigenetic biomarkers, or its workforce, and that trading and corporate communications continue while it engages with NYSE American to resolve the matter.

Regulatory process and timeline

VolitionRx faces a defined regulatory timetable and monitoring obligations under the NYSE American procedures. The company must outline specific remediation steps in its March submission and then demonstrate measurable progress over the subsequent 17 months to satisfy the exchange’s thresholds. The potential for delisting remains if targets are unmet, but the appeals process provides a procedural avenue to contest any adverse staff determination.

Research continuity and business operations

Industry observers note the notice focuses on listing compliance rather than clinical or product setbacks; VolitionRx continues to operate its research pipelines in liquid biopsy and epigenetic diagnostics while it addresses capital‑structure requirements. Management emphasizes that operational activities and investor communications proceed as normal during the exchange review.